SPE2DB22D2214 - PRIME VENDOR PHARM BRANCH-PHILADELPHIA

This IDC contract for Pharmaceuticals > Pharmaceutical Products was awarded in FY2022 on May 4, 2022 to Cencora by DLA Medical Directorate. There have been $47.7M in obligations to date with a ceiling value of $1,000M, showing a 5% burn rate so far on the contract. The contract was not competed under any preference program with 4 offers received. We expect a 3 year duration with ultimate completion date of Dec 30, 2025.

Cencora is a contractor located in PA, doing primarily Pharmaceuticals > Pharmaceutical Products work for Defense. The company receives $2.2B annually in federal awards (as of FY2020). Also, they have shown success winning IDC contracts concentrated mainly on a singular customer focused portfolio.

The Federal Government competes and awards an Indefinite Delivery Contract (IDC) to support requirements where the quantity and time of delivery are unknown. Typically referred to as Indefinite Delivery-Indefinite Quantity (IDIQ) contracts, the Government has the option of awarding a single or multiple award IDIQ. Once awarded, an IDIQ acts as a master agreement between the Federal Government and one or more contractors. On an as-needed basis, Federal buying organizations place orders, commonly referred to as Task Orders against an IDIQ, to purchase goods or services available through the IDIQ.

Read the full report

Buying Agency/Office

Defense»Defense Logistics Agency (DLA)»DLA Troop Support»DLA Medical Directorate

Read the full report